BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26396136)

  • 1. Transformation of alkylating regimen of thiotepa into tepa determines the disease progression through GSTP1 gene polymorphism for metastatic breast cancer patients receiving thiotepa containing salvage chemotherapy.
    Zhou X; Wang X; Song Q; Yang H; Zhu X; Yu J; Song G; Di L; Ren J; Shao H; Lyerly HK
    Int J Clin Pharmacol Ther; 2015 Nov; 53(11):914-22. PubMed ID: 26396136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic values of CYP2B6 genetic polymorphisms and metastatic sites for advanced breast cancer patients treated with docetaxel and thiotepa.
    Song Q; Zhou X; Yu J; Dong N; Wang X; Yang H; Ren J; Lyerly HK
    Sci Rep; 2015 Nov; 5():16775. PubMed ID: 26602960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine.
    Zhou X; Qiao G; Wang X; Song Q; Morse MA; Hobeika A; Gwin WR; Ren J; Lyerly HK
    Cancer Chemother Pharmacol; 2018 Feb; 81(2):365-372. PubMed ID: 29242966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer.
    Sugishita M; Imai T; Kikumori T; Mitsuma A; Shimokata T; Shibata T; Morita S; Inada-Inoue M; Sawaki M; Hasegawa Y; Ando Y
    Breast Cancer; 2016 Mar; 23(2):195-201. PubMed ID: 25008867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.
    Haroun F; Al-Shaar L; Habib RH; El-Saghir N; Tfayli A; Bazarbachi A; Salem Z; Shamseddine A; Taher A; Cascorbi I; Zgheib NK
    Cancer Chemother Pharmacol; 2015 Jan; 75(1):207-14. PubMed ID: 25428516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Germline TYMS genotype is highly predictive in patients with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy.
    Joerger M; Huitema AD; Boot H; Cats A; Doodeman VD; Smits PH; Vainchtein L; Rosing H; Meijerman I; Zueger M; Meulendijks D; Cerny TD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2015 Apr; 75(4):763-72. PubMed ID: 25677447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.
    Yao S; Barlow WE; Albain KS; Choi JY; Zhao H; Livingston RB; Davis W; Rae JM; Yeh IT; Hutchins LF; Ravdin PM; Martino S; Lyss AP; Osborne CK; Abeloff M; Hortobagyi GN; Hayes DF; Ambrosone CB
    Clin Cancer Res; 2010 Dec; 16(24):6169-76. PubMed ID: 21169260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of SOD2 and GSTP1 gene polymorphisms in Chinese patients with gastric cancer.
    Xu Z; Zhu H; Luk JM; Wu D; Gu D; Gong W; Tan Y; Zhou J; Tang J; Zhang Z; Wang M; Chen J
    Cancer; 2012 Nov; 118(22):5489-96. PubMed ID: 22517484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy.
    Deng X; Yang X; Cheng Y; Liu X; Li X; Zhao R; Qin C; Lu Q; Yin C
    Sci Rep; 2015 Sep; 5():14000. PubMed ID: 26354850
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Establishment of a multiplex ligation-dependent SNP genotyping method and its application in the detection of genes related to chemotherapeutic drugs in breast cancer].
    Tang JH; Zhao JH; Wu JZ; Lu JW; Pan LQ; Xu ZY
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):108-13. PubMed ID: 19538885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive potential role of glutathione S-transferases polymorphisms in response to chemotherapy and breast cancer prognosis.
    Yuan P; Yuan L; Xu BL; Wang CZ; Yang HZ; Li Y
    Genet Mol Res; 2015 Dec; 14(4):16675-81. PubMed ID: 26681014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salvage intracerebrospinal fluid thiotepa in breast cancer-related leptomeningeal metastases: a retrospective case series.
    Le Rhun E; Taillibert S; Devos P; Zairi F; Turpin A; Rodrigues I; Cazin JL; Pierret MF; André C; Dubois F; Bonneterre J; Chamberlain MC
    Anticancer Drugs; 2013 Nov; 24(10):1093-7. PubMed ID: 23962903
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of cyclophosphamide drug-metabolizing enzyme polymorphisms and chemotherapy-related ovarian failure in breast cancer survivors.
    Su HI; Sammel MD; Velders L; Horn M; Stankiewicz C; Matro J; Gracia CR; Green J; DeMichele A
    Fertil Steril; 2010 Jul; 94(2):645-54. PubMed ID: 19376514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients.
    Romero A; Martín M; Oliva B; de la Torre J; Furio V; de la Hoya M; García-Sáenz JA; Moreno A; Román JM; Diaz-Rubio E; Caldés T
    Ann Oncol; 2012 Jul; 23(7):1750-6. PubMed ID: 22052985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
    Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
    Pharmacogenet Genomics; 2008 Jun; 18(6):515-23. PubMed ID: 18496131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug metabolising enzyme polymorphisms and chemotherapy-related ovarian failure in young breast cancer survivors.
    Charo LM; Homer MV; Natarajan L; Haunschild C; Chung K; Mao JJ; DeMichele AM; Su HI
    J Obstet Gynaecol; 2021 Apr; 41(3):447-452. PubMed ID: 32496149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer.
    Bewick MA; Conlon MS; Lafrenie RM
    Breast Cancer Res Treat; 2008 Sep; 111(1):93-101. PubMed ID: 17922231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphisms of ALOX5AP and CYP3A5 increase susceptibility to ischemic stroke and are associated with atherothrombotic events in stroke patients.
    Yi X; Zhang B; Wang C; Liao D; Lin J; Chi L
    J Stroke Cerebrovasc Dis; 2015 Mar; 24(3):521-9. PubMed ID: 25534367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between glutathione S-transferase P1 (GSTP1), X-ray repair cross complementing group 1 (XRCC1) and 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) gene polymorphisms and response to chemotherapy in advanced gastric cancer.
    Ji M; Xu B; Jiang JT; Wu J; Li XD; Zhao WQ; Zhang HY; Zhou WJ; Wu CP
    Onkologie; 2013; 36(6):335-40. PubMed ID: 23774147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.